Developer docs
API playgroundTry for free, no card

Search company profiles

ExEm® Foam

Full company profile

uuid0095of5

Namestring
ExEm® Foam
Legal namestring
ExEm Foam Inc.
Websiteurl
exemfoam.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

ExEm Foam Inc., headquartered in Nashville, Tennessee, is a privately held specialty pharmaceutical company that manufactures and distributes ExEm Foam ((air polymer-type A) intrauterine foam), the only FDA-approved contrast agent for hysterosalpingo foam sonography (HyFoSy). The product is used during transvaginal ultrasound to assess fallopian tube patency in women with known or suspected infertility, producing approximately 127,000 micro air bubbles per ml that create a highly echogenic (bright white) image of patent tubes on standard 2D ultrasound, with optional 3D and High Definition Flow Doppler enhancement. The procedure is performed in-office, takes under 15 minutes on average, and avoids X-ray radiation, iodine contrast, and cervical tenaculum required by traditional hysterosalpingography (HSG), with clinical accuracy comparable to laparoscopy with dye per the FOAM Study and over 60 peer-reviewed publications.

The company targets U.S. fertility clinics, OBGYN practices, and hospital fertility departments, with named adopters including Mayo Clinic Rochester, NYU Langone Health, Johns Hopkins Medicine, and Texas Children's Hospital. Revenue is generated on a per-procedure consumable basis via the SendRx pharmacy hub, which handles EMR-integrated prescription fulfillment, benefits verification, and 2-day shipping, capped at $249 self-pay out-of-pocket per procedure; insurance coverage varies (medical benefit via J-code J3490 or pharmacy benefit). Commercial operations are supported by a direct field sales force of Account Managers and a Clinical Adoption Program delivered by Clinical Applications Specialists, alongside a multi-channel marketing presence at reproductive medicine conferences (ASRM, PCRS, ACOG, AIUM, MRSi). The product is a registered trademark of GISKIT PHARMA B.V.; in July 2023, Gedeon Richter Plc. acquired Giskit MD B.V. (owner of ExEm Foam and Gis-Kit assets globally excluding the U.S., China, and South Korea) from parent IQ Medical Ventures B.V. for approximately EUR 30 million, while ExEm Foam Inc. retained U.S. commercialization rights and operates as a subsidiary of XM Holding BV (Rotterdam, Netherlands).

Short descriptiontext

ExEm Foam Inc. is a Nashville-based specialty pharmaceutical company that manufactures and distributes the only FDA-approved foam contrast agent (ExEm Foam) for ultrasound-based fallopian tube patency assessment (HyFoSy) in women with suspected infertility, serving U.S. fertility clinics, OBGYN practices, and hospital fertility departments via per-procedure sales through the SendRx pharmacy hub.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNashville, United States
HQ citystring
Nashville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ultrasound contrast agents, fertility diagnostic devices, tubal patency testing, women's health imaging, gynecological ultrasound supplies
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Fertility Diagnostic Imaging
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model1 record
1ExEm Foam Product Sales
TypeOne Time License
Description

ExEm Foam Inc. generates revenue from the sale of its ExEm Foam ((air polymer-type A) intrauterine foam) contrast agent. Healthcare providers purchase ExEm Foam through SendRx, a pharmacy fulfillment partner. Prescriptions are submitted by providers via EMR or SendRx portal; SendRx performs benefits verification and ships the product to clinics. Self-pay patients may pay out-of-pocket at a maximum of $249 per procedure. Insurance coverage varies; ExEm Foam may be covered under medical benefit or pharmacy benefit.

exemfoam.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Others
Pricing details2 tiers
1Self-Pay / Out-of-Pocket: Maximum $249 per procedure
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Patients without insurance coverage or whose insurance does not cover ExEm Foam may self-pay through SendRx pharmacy at a maximum out-of-pocket cost of $249.

exemfoam.com
2Insurance-Covered: No cost to fully covered patients
ModelOtherBilling cadencePay-as-you-go
Notes

Depending on insurance coverage policies, ExEm Foam may be fully covered under a patient's insurance plan with no copay, deductible, or out-of-pocket costs. Patients are advised to verify with their insurance provider. ExEm Foam may be covered under medical benefit (J code: J3490) or pharmacy benefit.

exemfoam.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ExEm Foam Inc. manufactures and commercializes ExEm® Foam ((air polymer-type A) intrauterine foam), the only FDA-approved contrast agent for hysterosalpingo foam sonography (HyFoSy). The product is infused into the uterus via catheter and visualized in real-time on transvaginal ultrasound to assess fallopian tube patency in women with known or suspected infertility. The company complements the contrast agent with a Clinical Adoption Program that trains providers on the HyFoSy procedure, plus pharmacy-based ordering and reimbursement support via SendRx.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Less painful than X-ray HSG (hysterosalpingography) — significantly lower pain scores
+5 more records
Product overview1 text field

ExEm Foam Inc. offers a single flagship product: ExEm Foam ((air polymer-type A) intrauterine foam), the only FDA-approved contrast agent for hysterosalpingo foam sonography (HyFoSy). The product is used during an in-office ultrasound procedure to assess fallopian tube patency in women with known or suspected infertility. The company complements its core contrast agent with supporting services including a Clinical Adoption Program for training healthcare providers, and a SendRx-powered ordering and reimbursement platform for pharmacy fulfillment. The procedure uses standard 2D or 3D ultrasound equipment and provides real-time diagnostic results in under 15 minutes.

Product and service4 records
1ExEm Foam (air polymer-type A) intrauterine foam
CategoryPharmaceutical Contrast Agent
Description

ExEm Foam is the only FDA-approved contrast agent for use with Trans Vaginal Ultrasound (TVUS) in hysterosalpingo foam sonography (HyFoSy) procedures. It assesses tubal patency in women with known or suspected infertility by producing approximately 127,000 micro air bubbles per ml, creating a bright echogenic image visible on 2D/3D ultrasound with or without Doppler enhancement when the foam flows through patent fallopian tubes.

2HyFoSy Clinical Adoption Program
CategoryClinical Training and Adoption Services
Description

A structured training and onboarding service for fertility clinics, OBGYN practices, and hospitals implementing the HyFoSy procedure. It includes baseline ultrasound training tailored to clinic equipment (2D/3D), hands-on training with pelvic simulators, live patient training, and ongoing support from ExEm Foam Clinical Applications Specialists.

3SendRx Pharmacy Ordering and Reimbursement Service
CategoryPharmacy Distribution and Reimbursement Services
Description

Pharmacy fulfillment and reimbursement support service operated in partnership with SendRx. Healthcare providers submit prescriptions via EMR or the SendRx portal; SendRx performs benefits verification, handles billing, and ships ExEm Foam to clinics with standard 2-day shipping. Maximum out-of-pocket cost for uninsured patients is $249.

4Reimbursement Advisor Team Support
CategoryReimbursement and Coding Support Services
Description

A dedicated support service that assists fertility clinics, OBGYN practices, and physicians with coding guidance, reimbursement procedures, and insurance verification for ExEm Foam procedures. Reachable via phone and email (reimbursement@exemfoam.com).

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Gedeon Richter Plc.
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-07-20
Description

Gedeon Richter Plc. (Budapest, Hungary) acquired 100% of Giskit MD B.V. from IQ Medical Ventures B.V. for approximately EUR 30 million. Giskit MD B.V. owns ExEm Foam and Gis-Kit assets globally excluding the US, China, and South Korea (where they are pharma products). Both products are used in more patient-friendly ultrasound examinations. Richter's CEO described this as a perfect fit for the company's specialty strategy expanding its IVF portfolio, reinforcing presence in Women's Health.

exemfoam.com
Strategic tierCoreTypeTechnology or Integration
Description

ExEm Foam partnered with GE HealthCare for the 2023 ASRM Congress, using GE Voluson Ultrasound equipment at the ExEm Foam booth for hands-on HyFoSy training. The company also uses GE Voluson ultrasound systems in its clinical demonstrations and case studies (e.g., GE Voluson Swift, GE HealthCare Voluson Ultrasound E10, GE HealthCare Voluson S8).

3SendRx (ELA Pharmacy LLC dba SendRx)
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

SendRx is the exclusive pharmacy fulfillment partner for ExEm Foam in the US. Healthcare providers submit prescriptions via EMR or SendRx portal; SendRx handles benefits verification, billing, and 2-day shipping. Located at 1002 Bonaventure Dr, Elk Grove Village, IL 60007, NPI 1841051398. An auto-replenishment pharmacy hub is planned for early 2025.

exemfoam.com
Strategic tierCoreTypeOthers
Description

IQ Medical Ventures B.V. is the parent company of ExEm Foam Inc. (an affiliate). IQ Medical sold Giskit MD B.V. to Gedeon Richter in July 2023. IQ Medical acts as a Life Sciences incubator and investment suite for various startups in Gynecology, Fertility, Interventional Radiology & Cardiology, and Anesthesiology. ExEm Foam Inc. is headquartered in Nashville, TN; IQ Medical is headquartered in Rotterdam, Netherlands, with a satellite office in NYC.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Professor Mark Hans Emanuel, M.D., Ph.D., co-inventor of the ExEm Foam procedure, is affiliated with the Department of Gynecology and Reproductive Medicine at University Medical Center Utrecht, The Netherlands. He has contributed to the development and clinical validation of HyFoSy, presenting at ASRM and PCRS conferences.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Hologic is a major women's health diagnostics and imaging company with a portfolio spanning breast health, GYN surgical, and diagnostic solutions. Its scale and women's health focus make it a relevant incumbent comparable, particularly as ExEm Foam broadens from tubal patency into adjacent GYN diagnostic use cases.

TypeBroad incumbent
Description

CooperSurgical is a leading women's health and fertility diagnostics/IVF consumables company serving the same OBGYN, REI, and fertility clinic customer base as ExEm Foam. Its broader portfolio of IVF media, devices, and diagnostics makes it a relevant incumbent comparable.

TypeRegional player
Description

Gedeon Richter (which acquired Giskit MD B.V., the ExEm Foam/Gis-Kit global rights holder ex-US/China/SK) is a major Central and Eastern European pharmaceutical company with a growing women's health and IVF portfolio. As the parent of the global ExEm Foam franchise, Richter is the most direct regional strategic comparable controlling the asset.

TypeEmerging player
Description

Genea Biomedx develops and commercializes innovative instruments, consumables, and media for IVF and fertility clinics globally. It targets the same fertility clinic customer base as ExEm Foam and represents an emerging specialty comparable in fertility diagnostics.

TypeDirect peer
Description

Lantheus manufactures Definity (perflutren lipid microspheres), one of the leading FDA-approved ultrasound contrast agents in the US market. It competes with ExEm Foam in the ultrasound contrast category broadly and shares the US regulatory-approved contrast agent positioning.

TypeBroad incumbent
Description

FUJIFILM Irvine Scientific provides IVF and assisted reproductive technology media, devices, and diagnostics to fertility clinics globally. It targets the same fertility clinic procurement decisions as ExEm Foam and represents a relevant adjacent women's health/fertility comparable.

TypeDirect peer
Description

Bracco is a major manufacturer of ultrasound contrast agents (SonoVue/Lumason — sulfur hexafluoride microbubbles) used across multiple imaging indications. It is the most direct comparable to ExEm Foam in the ultrasound contrast agent category, though Bracco's products are not specifically indicated for tubal patency assessment.

TypeEmerging player
Description

GE HealthCare manufactures the Voluson ultrasound systems used to perform HyFoSy with ExEm Foam (Optison is also a GE ultrasound contrast agent). GE is both a commercial partner for training and conferences and an adjacent competitor in ultrasound imaging and contrast media.

TypeBroad incumbent
Description

Vitrolife is a global IVF and reproductive health products company offering media, consumables, and devices for fertility clinics. It serves the same fertility clinic customer base and competes for share of fertility clinic wallet as ExEm Foam expands its per-clinic footprint.

TypeBroad incumbent
Description

Philips is a global leader in diagnostic imaging including women's health ultrasound. Like GE, Philips competes broadly in ultrasound hardware and adjacent contrast workflows and serves the same OBGYN/REI end-prescribers as ExEm Foam.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ExEm® Foam

Fertility Diagnostic Imagingexemfoam.com

ExEm Foam Inc. is a Nashville-based specialty pharmaceutical company that manufactures and distributes the only FDA-approved foam contrast agent (ExEm Foam) for ultrasound-based fallopian tube patency assessment (HyFoSy) in women with suspected infertility, serving U.S. fertility clinics, OBGYN practices, and hospital fertility departments via per-procedure sales through the SendRx pharmacy hub.

What ExEm® Foam does

ExEm Foam Inc., headquartered in Nashville, Tennessee, is a privately held specialty pharmaceutical company that manufactures and distributes ExEm Foam ((air polymer-type A) intrauterine foam), the only FDA-approved contrast agent for hysterosalpingo foam sonography (HyFoSy). The product is used during transvaginal ultrasound to assess fallopian tube patency in women with known or suspected infertility, producing approximately 127,000 micro air bubbles per ml that create a highly echogenic (bright white) image of patent tubes on standard 2D ultrasound, with optional 3D and High Definition Flow Doppler enhancement. The procedure is performed in-office, takes under 15 minutes on average, and avoids X-ray radiation, iodine contrast, and cervical tenaculum required by traditional hysterosalpingography (HSG), with clinical accuracy comparable to laparoscopy with dye per the FOAM Study and over 60 peer-reviewed publications.

The company targets U.S. fertility clinics, OBGYN practices, and hospital fertility departments, with named adopters including Mayo Clinic Rochester, NYU Langone Health, Johns Hopkins Medicine, and Texas Children's Hospital. Revenue is generated on a per-procedure consumable basis via the SendRx pharmacy hub, which handles EMR-integrated prescription fulfillment, benefits verification, and 2-day shipping, capped at $249 self-pay out-of-pocket per procedure; insurance coverage varies (medical benefit via J-code J3490 or pharmacy benefit). Commercial operations are supported by a direct field sales force of Account Managers and a Clinical Adoption Program delivered by Clinical Applications Specialists, alongside a multi-channel marketing presence at reproductive medicine conferences (ASRM, PCRS, ACOG, AIUM, MRSi). The product is a registered trademark of GISKIT PHARMA B.V.; in July 2023, Gedeon Richter Plc. acquired Giskit MD B.V. (owner of ExEm Foam and Gis-Kit assets globally excluding the U.S., China, and South Korea) from parent IQ Medical Ventures B.V. for approximately EUR 30 million, while ExEm Foam Inc. retained U.S. commercialization rights and operates as a subsidiary of XM Holding BV (Rotterdam, Netherlands).

ExEm® Foam firmographics

Firmographics
Name
ExEm® Foam
Legal name
ExEm Foam Inc.
Website
https://exemfoam.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
ExEm Foam Inc. is a Nashville-based specialty pharmaceutical company that manufactures and distributes the only FDA-approved foam contrast agent (ExEm Foam) for ultrasound-based fallopian tube patency assessment (HyFoSy) in women with suspected infertility, serving U.S. fertility clinics, OBGYN practices, and hospital fertility departments via per-procedure sales through the SendRx pharmacy hub.
Ownership category
akta.pro rank

Where ExEm® Foam is headquartered

Location

Headquarters

HQ city
Nashville
HQ country
United States
HQ region
North America

Offices3 records

Markets served

ExEm® Foam business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Others

Revenue model

  1. ExEm Foam Product Sales: ExEm Foam Inc. generates revenue from the sale of its ExEm Foam ((air polymer-type A) intrauterine foam) contrast agent. Healthcare providers purchase ExEm Foam through SendRx, a pharmacy fulfillment partner. Prescriptions are submitted by providers via EMR or SendRx portal; SendRx performs benefits verification and ships the product to clinics. Self-pay patients may pay out-of-pocket at a maximum of $249 per procedure. Insurance coverage varies; ExEm Foam may be covered under medical benefit or pharmacy benefit.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goSelf-Pay / Out-of-Pocket: Maximum $249 per procedure
OtherPay-as-you-goInsurance-Covered: No cost to fully covered patients

Go-to-market motion4 records

Distribution channels4 records

Marketing channels7 records

ExEm® Foam product offering

Product offering

Core offering

ExEm Foam Inc. manufactures and commercializes ExEm® Foam ((air polymer-type A) intrauterine foam), the only FDA-approved contrast agent for hysterosalpingo foam sonography (HyFoSy). The product is infused into the uterus via catheter and visualized in real-time on transvaginal ultrasound to assess fallopian tube patency in women with known or suspected infertility. The company complements the contrast agent with a Clinical Adoption Program that trains providers on the HyFoSy procedure, plus pharmacy-based ordering and reimbursement support via SendRx.

Product overview

ExEm Foam Inc. offers a single flagship product: ExEm Foam ((air polymer-type A) intrauterine foam), the only FDA-approved contrast agent for hysterosalpingo foam sonography (HyFoSy). The product is used during an in-office ultrasound procedure to assess fallopian tube patency in women with known or suspected infertility. The company complements its core contrast agent with supporting services including a Clinical Adoption Program for training healthcare providers, and a SendRx-powered ordering and reimbursement platform for pharmacy fulfillment. The procedure uses standard 2D or 3D ultrasound equipment and provides real-time diagnostic results in under 15 minutes.

Differentiator

Problem solved

Functional benefit

Products and services

  • ExEm Foam (air polymer-type A) intrauterine foam ExEm Foam is the only FDA-approved contrast agent for use with Trans Vaginal Ultrasound (TVUS) in hysterosalpingo foam sonography (HyFoSy) procedures. It assesses tubal patency in women with known or suspected infertility by producing approximately 127,000 micro air bubbles per ml, creating a bright echogenic image visible on 2D/3D ultrasound with or without Doppler enhancement when the foam flows through patent fallopian tubes.
  • HyFoSy Clinical Adoption Program A structured training and onboarding service for fertility clinics, OBGYN practices, and hospitals implementing the HyFoSy procedure. It includes baseline ultrasound training tailored to clinic equipment (2D/3D), hands-on training with pelvic simulators, live patient training, and ongoing support from ExEm Foam Clinical Applications Specialists.
  • SendRx Pharmacy Ordering and Reimbursement Service Pharmacy fulfillment and reimbursement support service operated in partnership with SendRx. Healthcare providers submit prescriptions via EMR or the SendRx portal; SendRx performs benefits verification, handles billing, and ships ExEm Foam to clinics with standard 2-day shipping. Maximum out-of-pocket cost for uninsured patients is $249.
  • Reimbursement Advisor Team Support A dedicated support service that assists fertility clinics, OBGYN practices, and physicians with coding guidance, reimbursement procedures, and insurance verification for ExEm Foam procedures. Reachable via phone and email (reimbursement@exemfoam.com).

Quantifiable outcome

  • Less painful than X-ray HSG (hysterosalpingography) — significantly lower pain scores
  • +5 more outcomes

Companies that use ExEm® Foam

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles2 records

ExEm® Foam technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

Feature5 records

ExEm® Foam partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered major and core.

  • Gedeon Richter Plc.majorStrategic or Co-development Partner · 20 July 2023Gedeon Richter Plc. (Budapest, Hungary) acquired 100% of Giskit MD B.V. from IQ Medical Ventures B.V. for approximately EUR 30 million. Giskit MD B.V. owns ExEm Foam and Gis-Kit assets globally excluding the US, China, and South Korea (where they are pharma products). Both products are used in more patient-friendly ultrasound examinations. Richter's CEO described this as a perfect fit for the company's specialty strategy expanding its IVF portfolio, reinforcing presence in Women's Health.
  • GE HealthCarecoreTechnology or IntegrationExEm Foam partnered with GE HealthCare for the 2023 ASRM Congress, using GE Voluson Ultrasound equipment at the ExEm Foam booth for hands-on HyFoSy training. The company also uses GE Voluson ultrasound systems in its clinical demonstrations and case studies (e.g., GE Voluson Swift, GE HealthCare Voluson Ultrasound E10, GE HealthCare Voluson S8).
  • SendRx (ELA Pharmacy LLC dba SendRx)coreChannel Partner/ Reseller/ DistributorSendRx is the exclusive pharmacy fulfillment partner for ExEm Foam in the US. Healthcare providers submit prescriptions via EMR or SendRx portal; SendRx handles benefits verification, billing, and 2-day shipping. Located at 1002 Bonaventure Dr, Elk Grove Village, IL 60007, NPI 1841051398. An auto-replenishment pharmacy hub is planned for early 2025.
  • IQ Medical Ventures B.V.coreOthersIQ Medical Ventures B.V. is the parent company of ExEm Foam Inc. (an affiliate). IQ Medical sold Giskit MD B.V. to Gedeon Richter in July 2023. IQ Medical acts as a Life Sciences incubator and investment suite for various startups in Gynecology, Fertility, Interventional Radiology & Cardiology, and Anesthesiology. ExEm Foam Inc. is headquartered in Nashville, TN; IQ Medical is headquartered in Rotterdam, Netherlands, with a satellite office in NYC.
  • University Medical Center Utrecht (The Netherlands)coreStrategic or Co-development PartnerProfessor Mark Hans Emanuel, M.D., Ph.D., co-inventor of the ExEm Foam procedure, is affiliated with the Department of Gynecology and Reproductive Medicine at University Medical Center Utrecht, The Netherlands. He has contributed to the development and clinical validation of HyFoSy, presenting at ASRM and PCRS conferences.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

ExEm® Foam competitors and assessment

Company assessment

Broad incumbents

  • Hologic: Hologic is a major women's health diagnostics and imaging company with a portfolio spanning breast health, GYN surgical, and diagnostic solutions. Its scale and women's health focus make it a relevant incumbent comparable, particularly as ExEm Foam broadens from tubal patency into adjacent GYN diagnostic use cases.
  • CooperSurgical: CooperSurgical is a leading women's health and fertility diagnostics/IVF consumables company serving the same OBGYN, REI, and fertility clinic customer base as ExEm Foam. Its broader portfolio of IVF media, devices, and diagnostics makes it a relevant incumbent comparable.
  • FUJIFILM Irvine Scientific: FUJIFILM Irvine Scientific provides IVF and assisted reproductive technology media, devices, and diagnostics to fertility clinics globally. It targets the same fertility clinic procurement decisions as ExEm Foam and represents a relevant adjacent women's health/fertility comparable.
  • Vitrolife: Vitrolife is a global IVF and reproductive health products company offering media, consumables, and devices for fertility clinics. It serves the same fertility clinic customer base and competes for share of fertility clinic wallet as ExEm Foam expands its per-clinic footprint.
  • Philips (Healthcare): Philips is a global leader in diagnostic imaging including women's health ultrasound. Like GE, Philips competes broadly in ultrasound hardware and adjacent contrast workflows and serves the same OBGYN/REI end-prescribers as ExEm Foam.

Regional players

  • Bracco Imaging (GISKIT franchise counterpart): Gedeon Richter (which acquired Giskit MD B.V., the ExEm Foam/Gis-Kit global rights holder ex-US/China/SK) is a major Central and Eastern European pharmaceutical company with a growing women's health and IVF portfolio. As the parent of the global ExEm Foam franchise, Richter is the most direct regional strategic comparable controlling the asset.

Emerging players

  • Genea Biomedx: Genea Biomedx develops and commercializes innovative instruments, consumables, and media for IVF and fertility clinics globally. It targets the same fertility clinic customer base as ExEm Foam and represents an emerging specialty comparable in fertility diagnostics.
  • GE HealthCare: GE HealthCare manufactures the Voluson ultrasound systems used to perform HyFoSy with ExEm Foam (Optison is also a GE ultrasound contrast agent). GE is both a commercial partner for training and conferences and an adjacent competitor in ultrasound imaging and contrast media.

Direct peers

  • Lantheus Holdings: Lantheus manufactures Definity (perflutren lipid microspheres), one of the leading FDA-approved ultrasound contrast agents in the US market. It competes with ExEm Foam in the ultrasound contrast category broadly and shares the US regulatory-approved contrast agent positioning.
  • Bracco Imaging: Bracco is a major manufacturer of ultrasound contrast agents (SonoVue/Lumason — sulfur hexafluoride microbubbles) used across multiple imaging indications. It is the most direct comparable to ExEm Foam in the ultrasound contrast agent category, though Bracco's products are not specifically indicated for tubal patency assessment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

ExEm® Foam social profiles

Digital presence

ExEm® Foam compliance and trust

Trust signal

Compliance2 records

ExEm® Foam financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ExEm® Foam leadership team

Management profile

Number of profiles

Profiles1 record

ExEm® Foam funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ExEm® Foam M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ExEm® Foam

What does ExEm® Foam do?

ExEm Foam Inc. manufactures and commercializes ExEm® Foam ((air polymer-type A) intrauterine foam), the only FDA-approved contrast agent for hysterosalpingo foam sonography (HyFoSy). The product is infused into the uterus via catheter and visualized in real-time on transvaginal ultrasound to assess fallopian tube patency in women with known or suspected infertility. The company complements the contrast agent with a Clinical Adoption Program that trains providers on the HyFoSy procedure, plus pharmacy-based ordering and reimbursement support via SendRx.

Is ExEm® Foam a public or private company?

ExEm® Foam is a private company. It is classified as corporate owned and is currently operating.

When was ExEm® Foam founded?

ExEm® Foam was founded in 2011. It employs 11 to 50 people.

Where is ExEm® Foam based?

ExEm® Foam is headquartered in Nashville, United States, in the North America region.

How does ExEm® Foam make money?

One revenue line is on record: exEm Foam Product Sales.

Who are ExEm® Foam's main competitors?

Broad incumbents on record are Hologic, CooperSurgical, FUJIFILM Irvine Scientific, Vitrolife and Philips (Healthcare). Bracco Imaging (GISKIT franchise counterpart) is listed as a regional player. Emerging players are Genea Biomedx and GE HealthCare. Direct peers are Lantheus Holdings and Bracco Imaging.

Does ExEm® Foam have an API?

No public API is recorded for ExEm® Foam.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales